Chatbot Counselling for Smoking Cessation in Youths

November 17, 2025 updated by: Tzu Tsun Luk, The University of Hong Kong

Development of a Chatbot for Smoking Cessation Counselling for Youth Smokers Enrolled in the Youth Quitline: a Pilot Randomised Trial

The goal of this pilot trial is to develop and examine the trial feasibility and acceptability of a chatbot for smoking cessation in youth smokers. Specific aims include:

  1. To assess how many youth smokers accept the invitation to participate in the trial
  2. To assess the retention of the participants through 6 months after treatment initiation
  3. To assess the acceptability of the chatbot in terms of participants' compliance and usability rating of the chatbot.
  4. To estimate the intervention effect on abstinence outcomes
  5. To explore the participants' perception and experiences in the chatbot

Study Overview

Study Type

Interventional

Enrollment (Actual)

154

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Hong Kong, Hong Kong
        • HKU Youth Quitline

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Hong Kong residents aged 25 years or younger
  2. Used a tobacco product in the past 30 days, including cigarettes, electronic cigarettes, heated tobacco products, etc.
  3. Able to communicate in Chinese
  4. Own a smartphone with internet access

Exclusion Criteria:

  1. Diagnosed with a mental disease or on regular psychotropic drugs, or
  2. Participating in other ongoing smoking cessation studies.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Chatbot counselling
Smoking cessation counselling delivered by chatbot
Access to a chatbot that provides smoking cessation counselling based on the 5A's (Ask, Advice, Assess, Assist, Arrange follow-up) and 5R's (Risk, Relevance, Rewards, Relevance, Roadblocks, Repetition) tobacco intervention models from baseline to 3-month post-baseline.
Active Comparator: Peer counselling
Smoking cessation counselling delivered by peer counsellors
Usual treatment provided by the Youth Quitline, i.e., telephone counselling for smoking cessation based on the 5As and 5Rs models delivered by trained peer counsellors at baseline and 1 week, 1 month and 3 months post-baseline

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Biochemically-validated tobacco abstinence
Time Frame: 6 months after randomisation
Defined as a negative result of the iScreen OFD test for measuring salivary cotinine (with a cut-off of lower than 30ng/mL)
6 months after randomisation
Recruitment rate
Time Frame: Through recruitment completion, about 9 months
Number of participants divided by the number of eligible subjects
Through recruitment completion, about 9 months
Retention rate
Time Frame: 6 months
Number of participants completed the follow-up divided by the number of participants
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-reported 7-day point-prevalence tobacco abstinence
Time Frame: 3 months after randomisation
Being completely smoke-free in the past 7 days
3 months after randomisation
Self-reported 7-day point-prevalence tobacco abstinence
Time Frame: 6 months after randomisation
Being completely smoke-free in the past 7 days
6 months after randomisation
Self-reported 30-day point-prevalence tobacco abstinence
Time Frame: 3 months after randomisation
Being completely smoke-free in the past 30 days
3 months after randomisation
Self-reported 30-day point-prevalence tobacco abstinence
Time Frame: 6 months after randomisation
Being completely smoke-free in the past 30 days
6 months after randomisation
Self-reported 24-hour quit attempt
Time Frame: 3 months after randomisation
Serious attempt to quit smoking for 24 hours or longer in daily smokers
3 months after randomisation
Self-reported 24-hour quit attempt
Time Frame: 6 months after randomisation
Serious attempt to quit smoking for 24 hours or longer in daily smokers
6 months after randomisation
Self-reported 50% smoking reduction
Time Frame: 3 months after randomisation
Smoking reduction by at least half of the baseline daily number of cigarettes in continued smokers
3 months after randomisation
Self-reported 50% smoking reduction
Time Frame: 6 months after randomisation
Smoking reduction by at least half of the baseline daily number of cigarettes in continued smokers
6 months after randomisation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Tzu Tsun Luk, PhD, RN, The University of Hong Kong

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 7, 2024

Primary Completion (Actual)

June 25, 2025

Study Completion (Actual)

June 25, 2025

Study Registration Dates

First Submitted

June 17, 2024

First Submitted That Met QC Criteria

June 17, 2024

First Posted (Actual)

June 24, 2024

Study Record Updates

Last Update Posted (Actual)

November 20, 2025

Last Update Submitted That Met QC Criteria

November 17, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Smoking Cessation

Clinical Trials on Chatbot counselling

Subscribe